Publications
350 publications
Sort by: Date / Relevance
GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia
The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a ...
GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection
The National Health Care Institute has completed its assessment whether the products Rekambys® and Vocabria® can be included in ...
Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma
The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib ...
GVS advice ivacaftor (Kalydeco®) extension of further conditions
Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...
GVS advice dapagliflozin (Forxiga®) extension of further condition
The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...
Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer
Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...
Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA
Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...
GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia
The National Health Care Institute has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product ...
Advice on the clustering of combination products and ghost clusters in GVS
The Minister of Medical Care has asked Zorginstituut Nederland questions about the clustering of two categories of medicinal ...
GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)
The National Health Care Institute has completed its assessment whether elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in ...